Pfizer Reports Q4 Loss Driven by $4.4B Impairment, Reaffirms 2026 Guidance Amidst Non-COVID Growth
Summary
Pfizer reported a Q4 2025 loss driven by a significant $4.4 billion non-cash intangible asset impairment, while reaffirming its 2026 financial guidance and highlighting strong operational growth in its non-COVID portfolio.
Key Events
-
Q4 and Full-Year 2025 Financial Performance
Pfizer reported full-year 2025 revenues of $62.6 billion (2% operational decline) and Q4 2025 revenues of $17.6 billion (3% operational decline). The company posted a reported diluted loss per share of $(0.29) for Q4 2025, primarily due to impairment charges, but achieved adjusted diluted EPS of $0.66 for Q4 and $3.22 for the full year.
-
Significant Intangible Asset Impairment
The company recorded $4.4 billion in non-cash intangible asset impairment charges during Q4 2025, driven by changes in development plans and updated long-range commercial forecasts for various assets, including disitamab vedotin, Tukysa, and osivelotor.
-
Reaffirmed 2026 Financial Guidance
Pfizer reaffirmed its full-year 2026 financial guidance, projecting revenues in the range of $59.5 to $62.5 billion and adjusted diluted EPS in the range of $2.80 to $3.00.
-
Strong Non-COVID Portfolio Growth
Excluding contributions from Paxlovid and Comirnaty, revenues grew 6% operationally for the full year 2025 and 9% operationally for the fourth quarter, driven by products like Abrysvo, Oncology biosimilars, Eliquis, and the Prevnar family.
Analysis
Pfizer's latest earnings report presents a mixed financial picture. While the company demonstrated robust operational growth in its non-COVID product portfolio and reaffirmed its 2026 financial guidance, a substantial $4.4 billion non-cash intangible asset impairment charge in Q4 2025 led to a reported loss per share. This significant impairment, representing nearly 3% of the company's market capitalization, reflects a re-evaluation of certain pipeline assets and commercial forecasts, indicating challenges with specific investments. Investors should monitor the impact of these write-downs on future asset development and profitability, alongside the continued strong performance of the core non-COVID business and the progress of its diversified pipeline, particularly in areas like obesity and oncology. The strategic divestiture of the ViiV Healthcare stake provides a significant cash inflow, supporting capital allocation priorities.
At the time of this filing, PFE was trading at $26.41 on NYSE in the Life Sciences sector, with a market capitalization of approximately $151.6B. The 52-week trading range was $20.92 to $27.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.